Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients

Alessio Provenzani, Andrew Santeusanio, Erin Mathis, Monica Notarbartolo, Manuela Labbozzetta, Paola Poma, Ambra Provenzani, Carlo Polidori, Giovanni Vizzini, Piera Polidori, Natale D’Alessandro

Abstract

The introduction of tacrolimus in clinical practice has improved patient survival after organ transplant. However, despite the long use of tacrolimus in clinical practice, the best way to use this agent is still a matter of intense debate. The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or the action mechanism of a drug in the body. This variability seems to be correlated with the presence of genetic polymorphisms. Genotyping is an attractive option especially for the initiation of the dosing of tacrolimus; also, unlike phenotypic tests, the genotype is a stable characteristic that needs to be determined only once for any given gene. However, prospective clinical studies must show that genotype determination before transplantation allows for better use of a given drug and improves the safety and clinical efficacy of that medication. At present, research has been able to reliably show that the CYP3A5 genotype, but not the CYP3A4 or ABCB1 ones, can modify the pharmacokinetics of tacrolimus. However, it has not been possible to incontrovertibly show that the corresponding changes in the pharmacokinetic profile are linked with different patient outcomes regarding tacrolimus efficacy and toxicity. For these reasons, pharmacogenetics and individualized medicine remain a fascinating area for further study and may ultimately become the face of future medical practice and drug dosing.
observed blood trough levels of the drug. However, the question remains, should genotyping become a standard of practice in transplantation?

Provenzani A, Santusiano A, Mathis E, Notarbartolo M, Labbuzozza M, Poma P, Provenzani A, Polidori C, Vizzini G, Polidori P, D’Alessandro N. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. *World J Gastroenterol* 2013; 19(48): 9156-9173 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i48/9156.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i48.9156

INTRODUCTION

Transplantation is typically the standard of therapy for all patients with end-stage liver or kidney disease. Almost sixty years have passed since the first kidney transplant between identical twins was successfully performed, in 1954[1]. The first human liver transplant was performed almost 10 years later, in 1963. Another decade would pass before it was performed again. Since then, a significant effort has been made to improve the graft survival, as well as the patient outcome.

Despite the significant advances in terms of surgical techniques, tissue typing and patient care, most of the progress in organ transplantation is largely attributable to the recognized importance of immunosuppressive therapy[2,3].

Since the success of the transplant depends on a delicate balance between immunosuppression and rejection, reaching and maintaining an adequate therapeutic level by giving appropriate doses of immunosuppressive drugs is extremely important, especially in the first phases after the transplant.

The introduction of tacrolimus into clinical practice has undoubtedly improved patient survival after organ transplant. However, this drug is characterized by a restricted therapeutic index, a high inter- and intra-individual pharmacokinetic variability, including irregular oral bioavailability, and a series of severe adverse effects[4,5].

Given the high variability in blood levels and clinical response after administering fixed doses of tacrolimus, several studies have recently been conducted to find the optimal dosage of tacrolimus and thus to minimize its toxicity and to improve its risk/benefit ratio[6].

A number of studies have found a close correlation between the pharmacokinetic parameters of tacrolimus and the clinical outcome[7,8]. However, despite the long use of the drug in clinical practice, the best way to use tacrolimus is still a matter of intense debate[9,10].

The start of the genomic era has generated new research areas, such as pharmacogenetics, which studies the variability of drug response in relation to the genetic factors involved in the processes responsible for the pharmacokinetics and/or action mechanisms of a drug in the body[11,12].

This variability seems to be correlated with the presence of genetic polymorphisms, where, for example, some of the genes of the enzymes of phase I and II drug metabolic processes present, in at least 1%-2% of the population, allelic variants[13,14].

These variants can encode for different molecular isoforms of the same protein and, in most cases, consist of single nucleotide polymorphisms (SNPs), which may determine the production of isoforms differing by a single amino acid[14].

The variations in the DNA sequence of genes encoding for drug metabolizing enzymes can cause significant phenotypic differences in their expressivity and activity[15-17].

The clinical implications of genetic polymorphisms can include other aspects of drug bioavailability and elimination, as well as the pharmacodynamics of the drug and/or its metabolites and the therapeutic index. Despite the many genetic polymorphisms, only a small number of them have clinically significant consequences in terms of drug metabolism. This occurs mainly when two conditions coexist: the concerned metabolic pathway is the only pathway for the biotransformation of the drug and the drug has a low therapeutic index.

For all this reasons, pharmacogenetics research has begun to delve into genotyping approaches which may help to optimize the initiation and maintenance dosing of tacrolimus, to attain faster its target concentrations and to limit its dose-related adverse reactions[18]. This paper will review various studies that highlight the current genetic considerations in the dosing of tacrolimus and the future implications that this data may have for best individualizing the treatment with this drug.

TACROLIMUS PHARMACODYNAMICS AND PHARMACOKINETIC CHARACTERISTICS AND CONSIDERATIONS

The two calcineurin inhibitors utilized in transplantation are cyclosporine and tacrolimus.

Tacrolimus is a macrolide containing a 23-membered lactone ring produced by the *Streptomyces tsukubaensis* fungus (Figure 1). Its molecular weight is 822.05 Da[19]. Tacrolimus is now preferred to cyclosporine for its potency (10-100 times higher in *in vivo* and *in vitro* immunosuppression models) and for the reduction in episodes of rejection; it allows the use of lower doses of combination corticosteroids, thus reducing the possibility of adverse effects associated with such drugs[19,20].

Tacrolimus becomes biologically active only when it forms a complex with the immunophilin FK binding protein 12 (FKBP-12), that is different from the immunophilin (cyclophilin) to which cyclosporine binds. The complex FKBP-12-tacrolimus interferes with the transduction pathway of the intracellular calcium-dependent signal, which is a fundamental processes for the activation of T lymphocytes. The biological target of the complex
is the calcium/calmodulin-dependent protein phosphatase calcineurin, a fundamental molecule for the reactions necessary to the synthesis of various cytokines, including IL-2.

Tacrolimus acts as a molecular linker between the calcineurin/calmodulin complex and immunophilin, which are molecules that in normal conditions would not interact. The tacrolimus-FKBP-12 complex has a strong inhibitory dose-related effect on calcineurin phosphatase activity and consequently on IL-2 expression. The passage of the signal from the cytoplasm to the nucleus to activate the transcription of the IL-2 gene involves in fact a protein named nuclear factor of activated T-cell (NF-ATc). This protein is a T lymphocyte-specific transcription factor, the activity of which is correlated with the level of transcription of IL-2 after the T-cell receptor is activated[20,22]. The NF-ATc has two subunits, one of which is confined to the cytoplasm, while the other is mostly nuclear. An increase in intracellular calcium allows the cytoplasmatic unit to move into the nucleus, where it combines with the nuclear component and allows the formation of the IL-2 transcription factor. The signal transduction cascade starts at the presentation of the antigen to the T-cell receptor, which induces an increase in intracellular calcium, the activation of the calcium/calmodulin complex and the formation of the competent T-cell transcription factor (NF-ATc). The specific role of calcineurin is not entirely clear, but it is widely accepted that dephosphorylation induces the translocation into the nucleus of cytoplasmatic NF-ATc, a process that can be blocked by the immunophilin/drug complexes. The liaisons of DNA and the genetic transcription of IL-2 require both nucleic and cytoplasmatic subunits of NF-ATc. Tacrolimus stops transduction pathways of the signal and therefore hinders the IL-2 production by means of the intracellular action of the drug-FKBP-12 complex. The tacrolimus molecule can therefore be divided into two separate functional groups[22]: a binding group for the drug-FKBP-12 complex, and an effector group to bind to calcineurin (Figure 1).

Tacrolimus, a lipophilic drug, exhibits variable absorption and first pass metabolism when administered orally and this can influence its efficacy and toxicity. P-glycoprotein (P-gp, also known as ABCB1), an ATP-dependent membranous transporter which helps to protect the body against toxic xenobiotics by extruding these compounds out of cells and into the intestinal lumen and bile[23], can limit the oral bioavailability and influence the disposition of the calcineurin inhibitors[24-28]. In particular, the presence of P-gp in the intestine can limit tacrolimus absorption. Also, its presence in liver and kidney promotes tacrolimus efflux into bile and urine, respectively.

However, the conclusions drawn so far on the actual influence of P-gp SNPs on tacrolimus pharmacokinetics are highly controversial[29-31].

Additionally, CYP3A4 and CYP3A5, which exhibit variable levels of activity among transplant patients, are the primary enzymes responsible for the metabolism of the calcineurin inhibitors. The same drugs are also known inhibitors of P-gp and of the CYP enzyme system, so that they inhibit their own metabolism and excretion[32]. Other factors that can influence the pharmacokinetics of the calcineurin inhibitors include, but are not limited to, transplant type, baseline renal and hepatic function, concomitant use of corticosteroids, which induce both CYP3A and P-gp activity, patient age and race, time after transplantation, albumin and hematocrit concentration, trauma and food administration[33-40].

As a result, therapeutic drug monitoring is typically initiated after transplantation to facilitate the choice of the dosage of the calcineurin inhibitors and ensure appropriate levels of exposure to these medications. To date the most widely used parameter for the therapeutic monitor-
ing of tacrolimus is its trough whole blood concentration (C₀), which is measured 12 h after the dose administration and correlates well with the area under the concentration-time curve (AU(C₀)₁₂)⁴¹,⁴².

In practice, target trough levels for tacrolimus are typically set at around 10 ng/mL, but this can vary depending on individual patient characteristics, type of transplant and time after transplantation. Pharmacogenetics is estimated to account for between 20%-95% of drug variability in patients and this has prompted research to assess the feasibility of genotyping as a means to more rapidly and accurately determine the appropriate starting and maintenance dosages of the immunosuppressant⁴³.

Also to assess the economic advantage of the genotypic determinations, a number of pharmacodynamics studies have been undertaken to define the overall impact of a more delayed optimization of the drug dosage on patient outcomes. Typically these studies evaluate the effects of sub- or supra-therapeutic calcineurin inhibitor drug levels on graft life, patient mortality and development of various drug toxicities. The calcineurin inhibitors are known to be endowed with a number of possible deleterious effects including seizures, tremors, nephrotoxicity, malignancy, hyperglycemia, hypertension, insomnia, hyperesthesia and hyperlipidemia⁴⁴. They are also expensive and potentially life-long medications that can impose a heavy economic burden on patients and on the health care system in general. As a result, it would be beneficial to rapidly attain target blood trough drug levels in order to avoid side-effects, limit costs and assure appropriate level of immunosuppression.

**GENETIC POLYMORPHISMS**

To date, a number of SNPs have been studied in relation to the dosing of tacrolimus. However, alleles relating to the following three genes have been the most frequently studied and shown to be the most promising.

**CYP3A4**

CYP3A4, located in the liver, jejunum, colon, and pancreas, is polymorphically expressed, with at least 42 SNPs identified to date⁴⁴. The most known CYP3A4 polymorphisms are CYP3A4*1B (A392G)⁴⁵, CYP3A4*2 (Ser 222 Pro), and CYP3A4*3 (Met 445 Thr)⁴⁶. The primary polymorphism implicated and studied in the metabolism of the calcineurin inhibitors occurs at position 392 and is an A>G substitution that produces a transcriptional repressor⁴⁷. Consequently, the functional significance of this SNP is controversial and in vivo studies have generally failed to evidence an association between this polymorphism and the metabolism of various drugs⁴⁸,⁴⁹. This allele has been shown to occur in 2%-10% of Caucasians, 4.2%-11% of Hispanics, 35%-67% of African-Americans, and about 0% of Asians⁵⁰-⁶⁰.

**CYP3A5**

CYP3A5 in the liver, small intestine, stomach and kidney shows polymorphic expression, which is currently known to occur with at least 11 different SNPs. The most important polymorphism is that of the CYP3A5*3, which, in homozygous condition, determines the absence of the enzyme, since the variant sequences A>G at nucleotide 6986 in intron 3 of the CYP3A5 gene cause alternative splicing and the formation of a truncated protein that is not functional⁶¹,⁶². On the contrary, the G6986A (CYP3A5*1) allele is correlated with a high expression of the protein⁶³. Consequently, individuals that exhibit homozygous expression of the variant allele CYP3A5*3 are often referred to as “CYP3A5 non-expressers”. Patients with at least one CYP3A5*1 wild type allele are able to produce functional CYP3A5 enzymes and are known as “CYP3A5 expressers”; they have a different pattern of metabolite formation compared with the non-expressers, resulting also in the belief that CYP3A5 expression in the kidney may play a protective role against the development of nephrotoxicity by limiting the exposure of the organ to toxic metabolites⁶⁴-⁶⁶. Several studies have also suggested a link between CYP3A4*1B and the CYP3A5*1 wild type allele, as these two allelic variants appear generally to be inherited together⁶⁷-⁶⁹. Again the CYP3A5*1 wild type allele is differently distributed among the races and occurs in 5%-15% of Caucasians, 15%-35% of Asians, 25% of Mexicans, and 45%-73% of African-Americans⁷⁰.

**ABCB-1 (MDR-1, P-gp)**

The multidrug resistance-1 (MDR-1) gene, which encodes for the P-gp (ABCB-1) efflux pump in many organs and tissues (e.g., liver, kidney, hematopoietic barrier, blood testis barrier, maternal side of the placenta, adrenal glands and small intestines), is also polymorphically expressed, with at least 50 currently known SNPs. Its name derives from the fact that it was first found in tumor cell lines where it enhanced the resistance to anti-neoplastic drugs²³,⁷ⁱ-⁷⁴.

The most commonly studied ABCB1 polymorphisms include a C to T substitution at position 3435 on exon 26, a C to T substitution at position 1236 on exon 12, and a G to T/A substitution at position 2677 on exon 24³⁹. These three variant alleles have been shown to typically occur together, exhibiting a linkage disequilibrium that suggests that they may be further genetically linked³⁹-⁷⁰. Several studies have also suggested that this haplotype results in diminished P-gp expression in vivo and, in turn, in lower drug efflux activity. Theoretically this could result in tacrolimus accumulation in the blood stream and nervous system and, as a result, in symptoms of neurotoxicity³⁹,⁷⁰.

In addition, recent data have suggested that 3435C>T may reduce MDR-1 mRNA stability in the liver³⁹ or affect the insertion and folding of P-gp into the membrane, resulting in an altered substrate specificity of the transporter³⁹. This haplotype occurs in 5% of African Americans, 27%
of Asians, 32% of Caucasians and 35% of Mexicans[7].

Genetic Influence on Tacrolimus Pharmacokinetics

A number of clinical studies have begun to evaluate the actual impact of the previously described polymorphisms on tacrolimus dosing, efficacy and toxicity. We will now review a number of these studies and summarize their findings before analyzing the potential clinical implications of their data.

CYP3A4*1B

Data regarding the influence of CYP3A4 polymorphisms on tacrolimus pharmacokinetics are often inconsistent and confounded by the highly frequent linkage disequilibrium found between the CYP3A4*1B variant allele and the CYP3A5*1 wild-type allele[30,61,67-69,83]. The overall impact of the CYP3A4 genotype on tacrolimus dose requirements appears uncertain and should be further studied.

A study by Cho et al[84] on 70 Korean renal transplant patients found no association between CYP3A4*1B genotype and tacrolimus dose requirements up to 6 mo after transplantation[Table 1].

Another study, by Roy et al[85], confirmed these results, showing no correlation between the CYP3A4*1B (392A>G) SNP and tacrolimus pharmacokinetics (dose and C/Dose) when the influences of the CYP3A5 6986A>G SNP and ABCB1 polymorphisms were taken into account[87](Table 1).

In another study on 103 Spanish renal transplant patients, Gervasini et al[83] found that carriers of the CYP3A4*1B variant allele displayed tacrolimus concentrations that were on average 59% lower than those of patients with the CYP3A4*1/*1 genotype. The dose-adjusted trough levels observed were 145.59, 86.89, and 58.21 ng/mL per mg/kg per day for the 3A4*1-3A5*3, 3A4*1-3A5*1 and 3A4*1B-3A5*1 haplotypes, respectively, suggesting that the CYP3A4*1B-CYP3A5*1 haplotype may have a more profound impact on tacrolimus pharmacokinetics than the CYP3A5*1 allele alone (Table 1). However, because of the linkage disequilibrium between the CYP3A4 and CYP3A5 polymorphisms, all CYP3A4*1B carriers were also carriers of CYP3A5*1 allele.

CYP3A5*3

Many studies have confirmed that CYP3A5 polymorphisms have a major influence on the pharmacokinetics of tacrolimus. Consistently, patients homozygous for the CYP3A5*3 allele have shown lower dose requirements and higher whole blood trough levels of tacrolimus after transplantation, as well as clearances of the drug 25%-45% lower than patients expressing the CYP3A5*1 allele. In liver transplant patients, donor genotype has also generally been shown to have more important consequences on tacrolimus pharmacokinetics and dose requirements than recipient genet-

ics[58,63,88-93]. However, it still remains to be seen whether these alterations in the drug pharmacokinetics correlate or not to the patient clinical outcomes.

A study by Barrera-Pulido et al[94] on 53 liver transplant recipients found that recipients with the CYP3A5*1/*3 genotype receiving organs from *1/*3 donors failed to
achieve minimum blood tacrolimus levels at one month post-transplant (Table 2). Between days 30 and 60 post-transplant *3/*3 recipients from *1/*3 donors also had significantly greater tacrolimus dose requirements than recipients from *3/*3 donors.

These results also occurred in a study on 24 Native American kidney transplant recipients where it was observed that after 1 mo from transplant the patients required a significantly lower daily tacrolimus dose than a control group of Caucasian kidney transplant patients (0.03 mg/kg per day vs 0.5 mg/kg per day). To explain these data, many of these Native Americans, but not the Caucasians, were found to express the CYP3A5*3/*3 genotype, associated with diminished CYP3A5 enzymatic activity (Table 2). However, despite the differences in tacrolimus dose requirements, there were no differences in the drug trough levels or the incidence of nephropathy between the two study groups\[90\].

A study on 32 Caucasian liver transplant patients by Provenzani et al[91] found that dose requirements were significantly higher in patients receiving a liver with the CYP3A5*1 allele compared with donors who were homozygous for the *3 polymorphism (0.111 mg/kg per day vs 0.057 mg/kg per day). In the organ recipients, the CYP3A5*1 genotype tended to increase tacrolimus doses, though not to a statistically significant degree (Table 2).

In a case report, the same research group found that a 53-year-old Caucasian male who was homozygous for the CYP3A5*3 allele and had received a liver from a donor expressing the CYP3A5*1/*1 genotype required a dose two-fold higher than that reported in the literature for adult liver transplant patients. During the first, second and third week of therapy the patient received tacrolimus doses of 0.219, 0.287, and 0.273 mg/kg per day, respectively, while the trough drug levels obtained remained below the target of 10-12 ng/mL (4.6, 5.6 and 6.1 ng/mL at the first, second and third week of therapy, respectively). The patient reached a target level of 10.4 ng/mL only after one month of therapy. This corroborates that the CYP3A5*1 allele may be associated with increased hepatic metabolic capacity for tacrolimus and, consequently, delayed response to drug therapy\[91\].

The authors further confirmed these results when they looked at 51 Caucasian liver and 50 Caucasian kidney transplant recipients at 1, 3, and 6 mo post-transplant and again found that the presence of the CYP3A5*1 allele in liver donors, but not in recipients, had a statistically significant effect of decrease on the tacrolimus dose-adjusted trough levels. A similar result was also observed in the kidney transplant recipients, where the dose required to achieve and maintain target trough blood levels at 1, 3, and 6 mo was statistically lower in patients homozygous for the CYP3A5*3 allele compared with the patients expressing at least one copy of the wild type allele CYP3A5*3\[93\] (Table 2).

Another study by Cho et al[90] on 70 Korean renal transplant patients found that patients expressing either the CYP3A5*1/*3 or CYP3A5*1/*1 genotype, and thus a functional CYP3A5 protein, had tacrolimus dose requirements up to 80% greater than patients homozygous for the *3 allele up to 6 mo post-transplant (Table 2).

Glowacki et al[89] in a study on 209 French kidney transplant patients, also found that patients with at least one CYP3A5*1 allele had significantly higher tacrolimus dose requirements and lower trough drug levels than *3 homozygotes. However, these pharmacokinetic findings appeared to have no influence on the incidence of biopsy-proven acute rejection or on delayed graft function (Table 2). Patients were followed for a mean period of 21.8 mo, with no data suggesting that alterations in tacrolimus pharmacokinetics might have any significant impact on long-term clinical outcomes.

Another study, in 181 Japanese liver transplant recipients and 114 donors, showed that the level of CYP3A5 mRNA was significantly reduced in patients with livers carrying the CYP3A5*3/*3 genotype (0.41 amol/μg total RNA) vs the *1/*1 and *1/*3 genotypes (4.85 and 2.99 amol/μg total RNA, respectively). As a result, the dose-adjusted tacrolimus trough levels were significantly decreased, due to increased metabolism, in patients receiving a liver carrying the CYP3A5*1/*1 genotype\[92\] (Table 2).

Wei-lin et al[96], in a study on 50 Chinese liver transplant donors as well as recipients, found again that at one month after transplantation, recipients who received organs from CYP3A5*3/*3 donors had significantly higher dose-adjusted tacrolimus trough levels than the patients receiving livers from CYP3A5*1 expressers (Table 2). However, neither the donors’ ABCB1 genotype nor the recipients’ CYP3A5 genotype had any impact on the recipients’ tacrolimus pharmacokinetic profile, suggesting once more that in liver transplantation the donors’ CYP3A5 genetics, rather than that of the recipient, has a more important effect on tacrolimus dosing.

López-Montenegro Soria et al[97] studied 35 kidney transplant patients and found that during the first six weeks after transplant the tacrolimus concentration/dose ratios were remarkably lower for patients expressing at least one CYP3A5*1 allele compared with those homozygous for the CYP3A5*3 genotype (0.65 vs 1.45), due to higher drug clearances in CYP3A5*1 expressers (Table 2).

Another trial, by Shi et al[86], involving 216 Chinese liver transplant recipients concluded that daily tacrolimus dose requirements were higher for recipients with the CYP3A5*1/*1 genotype than patients expressing the *3/*3 genotype (3.0 mg vs 2.0 mg per day). Dose-adjusted tacrolimus trough levels were also lower in the *1/*1 genotype than *1/*3 expressers and in the *3 homozygotes (97.5, 124.8, and 144.4, respectively), suggesting in particular that CYP3A5 enzymatic activity is increased proportionally by the presence of one or two copies of the *1 allele (Table 2).

These results were supported by Jun et al[80] in a study of 506 Korean solid organ transplant recipients and 62 corresponding liver transplant donors, which concluded that the blood tacrolimus concentrations per adjusted
Chakkera et al. (2006) 24 native American and Caucasian control group Kidney recipients Native Americans had lower tacrolimus dose requirements than Caucasians at 1 mo after transplantation.

Provenzani et al. (2007) 32 Caucasian Liver recipients and donors Dose requirements significantly higher in the case of donors with the CYP3A5*1 allele at 1, 3 and 6 mo after transplantation.

Provenzani et al. (2007) 101 Caucasian Kidney recipients and liver (n = 51, recipients and donors) The study suggested also that CYP3A5 enzymatic activity is increased proportionally by the presence of the *1 allele.

Cho et al. (2007) 70 Korean Kidney recipients Those patients who had CYP3A5*1/*1 or *1/*1 genotypes had 80% higher tacrolimus dose requirements than patients homozygotes for *3 allele (up to 6 mo after transplantation).

Glowacki et al. (2007) 209 French Kidney recipients Patients with at least one copy of the CYP3A5*1 allele had significantly higher dose requirements and lower blood trough levels than patients homozygous for the *3 allele.

Goto et al. (2007) 181 Japanese Liver recipients and donors Patients with the CYP3A5*3/*3 genotype had reduced levels of CYP3A5 mRNA.

Wei-Lin et al. (2007) 50 Chinese Liver recipients and donors Those patients receiving a liver with the *3/*3 genotype had, at first month after transplantation, significantly higher tacrolimus dose-adjusted trough levels than those with at least one copy of the *1 allele.

López-Montenegro Soria et al. (2007) 35 Spanish Kidney recipients Concentration/dose ratios were remarkably lower in patients with at least one copy of the *1 allele than in patients homozygous for the *3 allele.

Shi et al. (2007) 216 Chinese Liver recipients Recipients with *1/*1 genotype had higher dosage requirements than those with *3/*3 genotype.

Jun et al. (2008) 588 Korean Kidney and liver recipients (n = 506), and liver donors (n = 62) Patients with the *3 alleles had higher tacrolimus dose-adjusted trough levels than patients with the *1 allele.

Elenos et al. (2009) 150 Belgian Liver donors Those patients with at least one *1 allele had at least 67% higher tacrolimus dose requirements.

Macphie et al. (2009) 119 White, 23 Black, 26 South Asian, 12 Middle Eastern Kidney recipients Patients with at least one copy of the wild-type *1 allele achieved twofold lower dose-normalized tacrolimus blood concentrations compared with CYP3A5*3/*3 homozygote patients.

Thervet et al. (2011) 168 Caucasian, 8 Black, 12 other Kidney recipients Pre-transplant dose adaptation, according to CYP3A5 genotype, is associated with improved achievement of the target blood trough levels.

Spiering et al. (2011) 81 Caucasian, 12 Black, 20 South Asian, 5 other Kidney recipients Tacrolimus dose requirements were significantly higher in patients expressing the wild type CYP3A5 genotype.

Chen et al. (2011) 120 Chinese Kidney recipients CYP3A5 expressers not receiving diltiazem required significantly higher tacrolimus doses than those who received the CYP inhibitor. In non-expressers, no significant difference in tacrolimus dose requirements was observed between the subjects treated with diltiazem and those who were not.

Provenzani A et al. Pharmacogenetic considerations for optimizing tacrolimus dosing

Table 2  Effect of CYP3A5 single nucleotide polymorphism on tacrolimus pharmacokinetics

| Authors       | Study population | Transplant type/analysis of recipients, donors or both | Findings |
|---------------|------------------|-------------------------------------------------------|----------|
| Barrera-Pulido et al. (2006) | 53 Caucasian | Liver recipients and donors CYP3A5*1/*3 recipients with *1/*3 donor livers had lower than minimum required blood tacrolimus levels at 1 mo after transplantation. *3/*3 recipients with *1/*3 donors had significantly greater tacrolimus dose requirements at 1 and 2 mo after transplantation. Native Americans had lower tacrolimus dose requirements than Caucasians at 1 mo after transplantation. No difference in blood trough levels or nephropathy between the two groups. |
| Provenzani et al. (2007) | 32 Caucasian | Liver recipients and donors Dose requirements significantly higher in the case of donors with the CYP3A5*1 allele at 1, 3 and 6 mo after transplantation. No statistically significant difference in dose requirements considering recipient’s genotypes. Tacrolimus dose in kidney recipients (n = 50) with CYP3A5*3/*3 genotype was significantly lower than in patients with at least one copy of the wild type allele. |
| Provenzani et al. (2007) | 101 Caucasian | Kidney (n = 50, recipients) and liver (n = 51, recipients and donors) Those patients who had CYP3A5*1/*1 or *1/*1 genotypes had 80% higher tacrolimus dose requirements than patients homozygotes for *3 allele (up to 6 mo after transplantation). |
| Cho et al. (2007) | 70 Korean | Kidney recipients Those patients who had CYP3A5*1/*1 or *1/*1 genotypes had 80% higher tacrolimus dose requirements than patients homozygotes for *3 allele (up to 6 mo after transplantation). |
| Glowacki et al. (2007) | 209 French | Kidney recipients Patients with at least one copy of the CYP3A5*1 allele had significantly higher dose requirements and lower blood trough levels than patients homozygous for the *3 allele. |
| Goto et al. (2007) | 181 Japanese | Liver recipients and donors Patients with the CYP3A5*3/*3 genotype had reduced levels of CYP3A5 mRNA. Dose-adjusted tacrolimus trough levels decreased in patients receiving a liver with the *1/*1 genotype. |
| Wei-Lin et al. (2007) | 50 Chinese | Liver recipients and donors Those patients receiving a liver with the *3/*3 genotype had, at first month after transplantation, significantly higher tacrolimus dose-adjusted trough levels than those with at least one copy of the *1 allele. |
| López-Montenegro Soria et al. (2007) | 35 Spanish | Kidney recipients Concentration/dose ratios were remarkably lower in patients with at least one copy of the *1 allele than in patients homozygous for the *3 allele. |
| Shi et al. (2007) | 216 Chinese | Liver recipients Recipients with *1/*1 genotype had higher dosage requirements than those with *3/*3 genotype. The study suggested also that CYP3A5 enzymatic activity is increased proportionally by the presence of the *1 allele. |
| Jun et al. (2008) | 588 Korean | Kidney and liver recipients (n = 506), and liver donors (n = 62) Patients with the *3 alleles had higher tacrolimus dose-adjusted trough levels than patients with the *1 allele. *1/*1 patients may be more rapid metabolizers than *1 heterozygous patients. |
| Elenos et al. (2009) | 150 Belgian | Liver donors Those patients with at least one *1 allele had at least 67% higher tacrolimus dose requirements. No influence of this SNP on rejection or graft dysfunction rates. |
| Macphie et al. (2009) | 119 White, 23 Black, 26 South Asian, 12 Middle Eastern | Kidney recipients Patients with at least one copy of the wild-type *1 allele achieved twofold lower dose-normalized tacrolimus blood concentrations compared with CYP3A5*3/*3 homozygote patients. |
| Thervet et al. (2011) | 168 Caucasian, 8 Black, 12 other | Kidney recipients Pre-transplant dose adaptation, according to CYP3A5 genotype, is associated with improved achievement of the target blood trough levels. |
| Spiering et al. (2011) | 81 Caucasian, 12 Black, 20 South Asian, 5 other | Kidney recipients Tacrolimus dose requirements were significantly higher in patients expressing the wild type CYP3A5 genotype. Intra-patient variability of tacrolimus clearance was not associated with at least one copy of the wild-type *1 allele. |
| Chen et al. (2011) | 120 Chinese | Kidney recipients CYP3A5 expressers not receiving diltiazem required significantly higher tacrolimus doses than those who received the CYP inhibitor. In non-expressers, no significant difference in tacrolimus dose requirements was observed between the subjects treated with diltiazem and those who were not. |
dose ratio was significantly higher in recipients with the *1/*3 genotype than in those with the *1/*1 one, and again higher in *3/*3 patients rather than in heterozygous *1/*3 recipients, suggesting that *1 homozygous patients may be even more rapid metabolizers than heterozygous patients expressing only one *1 allele (Table 2).

A study by Elens et al.\[99\] on 150 liver donors found that tacrolimus dose requirements were at least 67% higher among patients with at least one CYP3A5*1 allele and expressing hepatic CYP3A5 (Table 2). However, though hepatic CYP3A5 expression reduced blood tacrolimus levels and increased dose requirements, it failed to influence hepatic tacrolimus concentrations, which may be better related to liver graft outcome\[99\].

Another study, by Macphee et al.\[100\], in white and South Asian renal transplant patients, suggested that patients with at least one copy of the wild-type *1 allele achieved twofold lower dose-normalized tacrolimus blood concentrations compared with CYP3A5*3/*3 homozygote patients (Table 2).

In a prospective study involving 280 kidney transplant patients, Thervet et al.\[101\] found that a pre-transplant tacrolimus dose adaptation according to the CYP3A5 genotype is associated with fewer successive dose modifications and with a rapid achievement of target trough levels (Table 2).

In a more recent study by the Macphee’s group on 118 renal transplant patients, Spierings et al.\[102\] confirmed that the tacrolimus dose requirements were significantly higher in patients with the wild type CYP3A5 genotype (Table 2). However, they also found that intra-patient variability of tacrolimus clearance was not associated with the wild type CYP3A5 genotype.

Finally, in a 42-mo, prospective, randomized, parallel-controlled, open-label, single-center study, 62 Chinese CYP3A5 expressers and 58 non-expressers who had received kidney transplants were randomized to receive 30 mg of diltiazem (a known CYP inhibitor) three times daily in order to assess the efficacy of the drug as a calcineurin sparing agent. Patients who were known to be CYP3A5 expressers and did not receive diltiazem required significantly higher tacrolimus doses than the other groups (P = 0.017). Among the CYP3A5 non-expressers, there was not a significant difference in tacrolimus dose requirements between the subjects treated with diltiazem and those who were not. This was expected, as the proposed mechanism for diltiazem as a calcineurin sparing agent involves the inhibition of the metabolism of tacrolimus through the CYP3A5 pathway (Table 2). This suggests that CYP3A5 expressers are more susceptible to diltiazem-induced tacrolimus dose reductions and may possibly provide the prescribers with a mechanism able to limit the cost of immunosuppressive therapy as well as to treat concomitant hypertension in transplant patients\[101\].

**ABC1**

Data showing a link between a patient’s ABC1 genotype and tacrolimus pharmacokinetics have been inconsistent. Though most studies have failed to find any association, some clinical trials have found a significant relation between the ABC1 genotype and tacrolimus dosing. These results are often confounded by the linkage disequilibrium expressed among genetic variants, underscoring the need for further research on ABC1 genetics before a definitive conclusion can be reached.

Provenzani et al.\[103\], in a study on 32 Caucasian liver transplant patients, found no influence of the 3435C>T and 2677G>T SNPs on tacrolimus dose requirements (Table 3). A study by Cho et al.\[104\] on 70 Korean renal transplant patients also found no association between the ABC1 genotype and tacrolimus dose requirements up to 6 mo after transplantation (Table 3).

Further supporting these results, Shi et al.\[105\] found that in 216 Chinese liver transplant patients, there was no significant association between any of the ABC1 polymorphisms and daily tacrolimus dose requirements or trough levels (Table 3).

This was again confirmed by Jun et al.\[106\], who studied 506 Korean solid organ transplant recipients and 62 corresponding liver transplant donors. They found no correlation between the ABC1 patient genotype and tacrolimus concentration to adjusted dose ratios (Table 3).

Gervasini et al.\[107\] also found that, in 103 renal transplant patients, none of the ABC1 polymorphisms were associated with altered dose-adjusted trough levels or increased tacrolimus-induced toxicity (Table 3).

Another study by Kuypers et al.\[108\] found that in 304 kidney transplant patients the ABC1 genotype had no significant impact on tacrolimus exposure parameters or dosing requirements (Table 3).

A study by Provenzani et al.\[102\] on 51 liver and 50 kidney transplant patients found no association between the ABC1 polymorphisms and tacrolimus dosing among liver transplant patients, but did observe that kidney transplant patients carrying the 2677T/A allele required a significantly higher daily tacrolimus dose than patients homozygous for the wild type allele (Table 3).

Another study by Kuypers et al.\[106\] found that in 181 liver transplant recipients and 114 donors found that, in the first week post-transplantation, the recipients who displayed the wild type MDR-1 allele and thus high ABC-1 activity in the intestine, had lower dose-adjusted tacrolimus trough levels than patients who displayed MDR-1 variant alleles and were low ABC-1 expressers, even among patients with the same liver CYP3A5 genotype. However, this difference was not observed after two weeks, suggesting that MDR-1 expression in the intestine may contribute to tacrolimus trough levels in the first week post-transplantation; afterwards the transplanted liver would achieve a greater metabolic capacity and becomes the main organ that influences tacrolimus pharmacokinetics\[108\] (Table 3).

This was supported by Herrero et al.\[109\] in a study on 71 renal transplant patients, in which it was found that patients with the wild type ABC1 genotype tended to have more stable tacrolimus concentrations within the
therapeutic range during the first 3 mo after transplantation, while patients expressing polymorphic ABCB1 alleles showed a mean increase in the drug blood concentrations greater than 60% due to a diminished elimination capacity by the body (Table 3).

A study on 50 Chinese liver transplant donors and recipients also evidenced that daily tacrolimus dose requirements were significantly higher in recipients carrying the wild type ABCB1-3435CC rather than the C3435T allele at the weeks 1 and 2 and at 1 mo post-transplantation (Table 3). These data suggested that in Chinese people the ABCB1 genotype plays a dominant role in the intestinal tacrolimus pharmacokinetics: in fact patients with the wild type MDR-1 genotype are more likely to extrude tacrolimus from enterocytes and therefore need a higher daily dose to achieve adequate blood tacrolimus levels.

López-Montenegro Soria et al., in a study on 35 renal transplant patients, also found that patients expressing the wild type ABCB1-3435CC genotype showed up to 40% lower concentration/dose ratios compared with patients carrying variant alleles (Table 3).

Finally, a study by Elens et al. on 150 liver transplant patients found that ABCB1 genetic polymorphisms in the donors significantly influenced tacrolimus concentrations in the liver, but failed to influence the drug mean blood levels. The ABCB1-1236C>T polymorphism was also associated with improved liver function and significantly lower Banff scores compared with the situation of patients with the wild type allele (Table 3). These data suggest that ABCB1 polymorphisms may be important in liver transplant patients due to their effects on tacrolimus levels in the liver, which, as already said, may be a good marker to predict the liver graft rejection.

INFLUENCE OF GENETICS ON TACROLIMUS PHARMACODYNAMICS

Despite many studies have demonstrated a strong association between CYP3A5 genotype and alterations in tacrolimus pharmacokinetics, the results do not provide consistent evidence of organ rejection or drug-related toxicity as a consequence of genotype-related sub- or supra-therapeutic immunosuppression. This is likely due to the fact that the

---

**Table 3.** Effect of ABCB1 single nucleotide polymorphism on tacrolimus pharmacokinetics

| Authors                  | Study Population | Transplant type/analysis of recipients, donors or both | Findings                                                                                                                                 |
|--------------------------|------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Provenzani et al.⁹⁹      | 32 Caucasian     | Liver recipients and donors                            | No influence of 3435C>T and 2677G>T SNPs on tacrolimus dose requirements                                                               |
| Cho et al.⁹⁴             | 70 Korean        | Kidney recipients                                      | No association between ABCB1 genotype and tacrolimus dose requirements                                                                 |
| Shi et al.⁶⁶             | 216 Chinese      | Liver recipients                                       | No association between any ABCB1 SNPs and tacrolimus dose requirements or blood trough levels                                          |
| Jun et al.⁹⁴             | 568 Korean       | Kidney and liver recipients (n = 506), and liver donors (n = 62) | No correlation between ABCB1 genotype and tacrolimus dose-adjusted blood trough levels                                               |
| Gervasiini et al.⁶⁶      | 103 Spanish      | Kidney recipients                                      | None of the ABCB1 polymorphisms were associated with changes in dose-adjusted blood trough levels and in dose requirements             |
| Kuypers et al.⁸⁰         | 304 Belgian      | Kidney recipients                                      | No significant impact of ABCB1 genotype on tacrolimus exposure parameters or dosing requirements                                         |
| Provenzani et al.⁹⁹      | 101 Caucasian    | Kidney (n = 50) and liver (n = 51, recipients and donors) | No ABCB1 influence on dosing in liver transplant patients                                                                            |
| Goto et al.⁶⁶            | 181 Japanese     | Liver recipients and donors                            | Patients receiving kidney transplant carrying the 2677T/A allele required significantly higher doses than those patients with the wild type allele |
| Herrero et al.⁶⁴         | 71 Spanish       | Kidney recipients                                      | Patients with wild type ABCB1 alleles had more stable tacrolimus concentrations within the therapeutic range during the first 3 mo |
| Wei-Lin et al.⁸⁰         | 50 Chinese       | Liver recipients and donors                            | Patients with the wild type ABCB1-3435CC allele had significantly higher tacrolimus dose requirements than those with C3435T at 1 and 2 wk and 1 mo after transplantation |
| López-Montenegro Soria et al.⁶⁷ | 35 Spanish       | Kidney recipients                                      | Wild type ABCB1 3435CC patients had 40% lower concentration/dose ratios than those patients with variant alleles |
| Elens et al.⁹⁶           | 150 Belgian      | Liver donors                                           | ABCB1 genetic polymorphisms significantly influence tacrolimus hepatic concentrations, but have no effect on tacrolimus blood levels  |

In a study by Elens et al. on 150 liver transplant patients found that ABCB1 genetic polymorphisms in the donors significantly influenced tacrolimus concentrations in the liver, but failed to influence the drug mean blood levels. The ABCB1-1236C>T polymorphism was also associated with improved liver function and significantly lower Banff scores compared with the situation of patients with the wild type allele (Table 3). These data suggest that ABCB1 polymorphisms may be important in liver transplant patients due to their effects on tacrolimus levels in the liver, which, as already said, may be a good marker to predict the liver graft rejection.
patients are closely monitored in the first period following transplantation and undergo dose adjustments to more rapidly achieve target trough drug levels. However, different clinical trials have begun to explore the practical pharmacodynamics implications of genetic alterations in tacrolimus pharmacokinetics, and some of them have found clinically significant results.

Jun et al. found no significant difference in the incidence of organ rejection in 506 Korean solid organ transplant recipients and 62 liver transplant donors after comparing both patients’ genotypes and mean tacrolimus concentration per an adjusted dose ratios (Table 4).

Another study by Chen et al. on 120 Chinese kidney transplant patients who were a mix of CYP3A5 expressers and non-expressers, found that patients who received genotype-guided initial tacrolimus dosing achieved target drug levels more rapidly than the patients who received a standard protocol dose of tacrolimus (90.9% vs 27.3% of patients in target range, respectively). However, no differences were observed between the two groups with respect to the incidence of leukocytopenia, nephropathy, abnormal liver function, hyperlipidemia, diarrhea or hyperglycemia (Table 4).

In a prospective, open-label, observational cohort study, Kuypers et al. found that among 304 kidney transplant patients, the proportion of patients who developed new-onset diabetes after transplant (NODAT) was significantly higher in patients with delayed graft function and who displayed trough tacrolimus levels greater than 15 ng/mL on the first day post-transplantation. In this study, the presence of the CYP3A5*1 allele and a functional CYP3A5 enzyme appeared to attenuate the effects of delayed graft function on initial tacrolimus exposure and dose requirements, suggesting that CYP3A5 expressers may be at lower risk of NODAT following kidney transplantation due to diminished exposure to potentially toxic levels of tacrolimus (Table 4).

In a separate study, but in the same population of 304 kidney transplant patients, Kuypers et al. found that calcineurin-inhibitor-associated nephrotoxicity (CNIT) was more common in patients carrying the CYP3A5*1 allele than in patients who did not (32.4% vs 15.2%). Additionally, these researchers observed that CNIT developed in 25% of patients with dose requirements exceeding 0.2 mg/kg per day, 16.2% of patients with doses between 0.1-0.2 mg/kg per day and 4.5% of patients needing less than 0.1 mg/kg per day; the carriers of the CYP3A5*1 allele predominantly comprised the higher tacrolimus dose ranges. These results suggest that patients expressing the CYP3A5*1 allele and a functional CYP3A5 enzyme may be predisposed to developing CNIT following transplantation due to greater daily tacrolimus dose requirements. This was observed especially in patients who continued corticosteroid therapy (Table 4). However, the incidence of delayed graft function and post-transplant diabetes mellitus was not different between CYP3A5 expressers and non-expressers.

In a more recent study, on 319 Hispanic kidney transplant patients, other authors found that the SNPs in the cytoplasmic nuclear factor of activated T cells 4 (NFATc4) gene, which is expressed in pancreatic islets, may confer a certain protection or also a predisposition with regard to NODAT; in particular, the patients carrying the SNP (rs10141896) T allele (T-T-T-T-G haplotype) showed a protection from NODAT, while patients homozygous for the C-C-C-G-G haplotype were associated with increased risk of NODAT. Furthermore, the authors found that the use of sirolimus and tacrolimus and a more advanced age (> 45 years) were also possibly correlated to the development of NODAT (Table 4).

Cho et al. found that in 70 Korean renal transplant patients tacrolimus toxicity was more frequent in the subjects with CYP3A5*1 alleles, which had significantly higher dose requirements of the drug than patients expressing the *3 polymorphism (Table 4). Despite these findings, the study found no difference in the rate of graft survival between the various genotype-differentiated study groups.

A study by Barrera-Pulido et al. on 53 liver transplant recipients found that patients with the CYP3A5*3/*3 genotype receiving the organs from donors with an ABCB1 polymorphism had a lower frequency of renal dysfunction, the same rejection rate and a higher rate of diabetes than the other groups studied (Table 4).

However, Shi et al. found that in 216 Chinese liver transplant patients, carriers of the CYP3A5*3 allele had an increased risk of early renal injury compared with expressers of the CYP3A5*1 allele, possibly due to decreased enzymatic activity and higher dose-adjusted trough concentrations (Table 4).

CONSIDERATIONS FOR FURTHER GENETIC RESEARCH

In addition to the previously discussed genetic polymorphisms, a number of other variants that may potentially influence the pharmacokinetics and pharmacodynamics of tacrolimus and transplant outcomes have been proposed for further study.

P450 oxidoreductase*28

Cytochrome P450 oxidoreductase (POR) is essential for the electron donation in the microsomal-CYP450-mediated mono-oxygenation that catalyzes the metabolism of approximately 85%-90% of therapeutic drugs. More than 40 SNPs have been identified in the POR gene, and it has been suggested that several of these mutations, specifically the POR*28 C>T polymorphism, can increase this
activity and alter the baseline metabolic capacity of several CYP isoenzymes. The *28 allelic variant has been found to be expressed in 19.1% of African-Americans, 26.4% of Caucasian Americans, 31.0% of Mexican Americans, and 36.7% of Chinese Americans[108].

A study by Zhang et al[109] on 71 healthy Chinese volunteers found that the mean tacrolimus AUC(0-24) and Cmax (71.5 and 17.6 ng/mL, respectively) for patients who were CYP3A5 expressers as well as carriers of the wild type CC POR genotype were 1.53 and 1.57 fold higher than those (46.7 and 11.2 ng/mL) observed in patients carrying POR allelic variants. No significant differences were observed between POR*28-CC homozygotes and POR*28-T carriers in CYP3A5 non-expressers, suggesting that the POR genotype is important in altering tacrolimus metabolism only in CYP3A5 expressing patients.

These results were supported by a cohort study of de Jonge et al[110] on 298 renal transplant recipients, which it was found that in CYP3A5 expressers, POR*28T allele carriers had lower trough tacrolimus levels in the first three days post-transplant and took longer to reach the target trough levels when compared with POR*28CC homozygous patients. These patients with the variant POR genotype ultimately had 25% higher tacrolimus dose requirements than patients expressing the wild type allele. Again, POR*28 polymorphisms were found to have no influence on tacrolimus pharmacokinetics in CYP3A5 non-expressers, and no differences in transplant outcomes were observed between the study groups.

**CYP3A7**

Previously thought to be confined to the fetal liver, CYP3A7 has been found to be expressed in up to 54-88% of adult livers, but with a diminished metabolic capacity compared with that observed in children[111,112]. The role of CYP3A7 in the biotransformation of the CYP3A substrates in the adult liver and intestine is unknown. However, it was observed that CYP3A7 expression in the adult liver and intestine is increased in the carriers of the CYP3A4*1C allele[112,113]. This allele has a very low frequency (3%) both

---

**Table 4 Effect of various single nucleotide polymorphisms on tacrolimus pharmacodynamics**

| Authors          | Study Population | Transplant type/analysis of recipients, donors or both | Findings                                                                                                                                                                                                 |
|------------------|------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jun et al[93]    | 568 Korean       | Kidney and liver recipients (n = 506), and liver donors (n = 62) | No difference in incidence of organ rejection between different genotypes                                                                                                                                   |
| Chen et al[93]   | 120 Chinese      | Kidney recipients                                      | Patients that received genotype-guided initial tacrolimus dosing vs standard protocol dose were more likely to achieve target drug levels                                                                 |
| Jacobson et al[93] | 945 (different ethnicities) | Kidney recipients | No influence on incidence of adverse effects between CYP3A5 expressers and non-expressers. Polymorphism was not associated with an increased or decreased risk of tacrolimus-related nephrotoxicity. |
| Kuypers et al[94] | 273 White, 3 Hispanic, 24 North African, 2 African, 2 Asian | Kidney recipients | Every increase in tacrolimus blood trough level of 1 ng/mL increased the risk of early tacrolimus nephrotoxicity by 22%                                                                                      |
| Kuypers et al[94] | 273 White, 3 Hispanic, 24 North African, 2 African, 2 Asian | Kidney recipients | Patients expressing the CYP3A5*1 allele and a functional CYP3A5 enzyme may be predisposed to developing calcineurin-inhibitor-associated nephrotoxicity (CNIT) following transplantation due to greater daily tacrolimus dose requirements. |
| Chen et al[95]   | 319 Hispanic     | Kidney recipients                                      | This was observed especially in patients continuing corticosteroid therapy                                                                                                                                  |
| Cho et al[94]    | 70 Korean        | Kidney recipients                                      | CYP3A5 expressers may be at lower risk of new-onset diabetes after transplant (NODAT) due to diminished exposure to potentially toxic tacrolimus levels                                                                 |
| Barrera-Pulido et al[94] | 53 Spanish | Liver recipients and donors | No difference in graft survival between the two genotypes. Patients with CYP3A5*3/3 allele receiving livers with an ABCB1 SNP had lower frequency of renal dysfunction, same rejection rate and higher diabetes rate. |
| Shi et al[96]    | 216 Chinese      | Liver recipients                                       | Patients with the CYP3A5*3 allele had greater risk of early renal injury than the patients with the *1 allele.                                                                                             |
in Caucasians and African-Americans\textsuperscript{[63]}.

Although tacrolimus is believed to be a substrate for the CYP3A7 enzyme, the influence of CYP3A7 metabolism on the pharmacokinetics of tacrolimus requires further study, especially in pediatric patients\textsuperscript{[99]}.

**CYP3A4*18B**

This CYP3A4 polymorphism appears only in Asian (25\%-30\%)\textsuperscript{[114]}, primarily Korean, populations, but has been linked with a potentially increased metabolic capacity of the CYP3A4 enzyme. It has also been shown that carriers of the CYP3A4*1 allele are more likely to possess the CYP3A4*18B allele. As a result, further study is required to determine whether linkage disequilibrium with the CYP3A5*1 allele may confound the observed metabolic effects of the CYP3A4*18B polymorphism. One study, by Jun \textit{et al}\textsuperscript{[98]}, found no correlation between the CYP3A4*18 allele and tacrolimus concentration to adjusted dose ratios in 506 Korean solid organ transplant recipients. A study of 22 healthy Chinese people showed a higher tacrolimus clearance in patients carrying the CYP3A4*18B allele with respect to those carrying the CYP3A4*1 allele\textsuperscript{[115]}. A more recent study, by Li \textit{et al}\textsuperscript{[116]}, on 83 Chinese renal transplant recipients confirmed the results of the previous study. It found that the tacrolimus-dose-adjusted trough concentration was significantly lower in patients carrying the CYP3A4*18B allele compared with patients with the CYP3A4*1 allele.

**CYP3A4*22**

A new CYP3A4 allele (CYP3A4*22; rs35599367 C>T in intron 6) was recently discovered and also investigated in transplant patients\textsuperscript{[117,118]}.

In particular, a study on 185 renal transplant patients, mostly Caucasians, evaluated the impact of this new SNP on tacrolimus pharmacokinetics. It showed that in the first year after transplantation, patients carrying one or two T alleles required significantly lower tacrolimus doses (33\%) compared with patients homozygous for the wild-type C allele\textsuperscript{[118]}. The authors attributed the result to the fact that this CYP3A4*22 SNP is significantly linked to reductions in CYP3A4 mRNA production and enzyme activity in human livers\textsuperscript{[118-120]}. This SNP is relatively frequent in Caucasians (2.5\%-6.9\%). The authors also suggested that, though further studies are necessary, that pre-transplant genotyping of the CYP3A4 C>T could reduce the risk of achieving supra-therapeutic tacrolimus levels\textsuperscript{[118]}. However, in a study done on Brazilian renal transplant patients, CYP3A4*22 was not associated with changes in tacrolimus dose requirements\textsuperscript{[119]}.

**CYP2C8 and CYP2J2**

These enzymes, which are polymorphically expressed in the kidney, are involved in the synthesis of epoxyeicosatrienoic acids that play a protective role against acute rejection and toxicity by acting as vasodilators to maintain adequate renal perfusion and limit hypertension.

In a study on 163 liver transplant patients the authors found that patients with the \textit{CYP2C8*3} variant genotype appeared to be at higher risk of tacrolimus-induced kidney disease, possibly because of reduced formation of the kidney protecting epoxyeicosatrienoic acids\textsuperscript{[122]}. In another study, on 103 renal transplant patients, the authors found a higher incidence of delayed graft function and nephrotoxicity in patients homozygous for the \textit{CYP2C8*3} genotype, associated with reduced epoxyeicosatrienoic acid production and, consequently, less vasodilator activity\textsuperscript{[123]}.

In a more recent study the same research group could associate both \textit{CYP2C8*3} and donor age (> 48 years) with a higher incidence of delayed graft function and poorer creatinine clearance\textsuperscript{[124]}.

**SLCO1B1**

This gene is responsible for expressing the organic anion transporting polypeptides \textit{OATP1B1} and \textit{OATP1B3}. These transporters play a role in the transport of multiple compounds from the portal vein to hepatocytes and in the biliary excretion of many drugs. Recently, Elens \textit{et al}\textsuperscript{[99]} found that the 388A>G and 521T>C polymorphisms in the \textit{SLCO1B1} gene influenced tacrolimus trough blood concentrations after the administration of the first dose in 150 liver transplant patients. In this study, patients expressing the 388 polymorphism showed a lower mean tacrolimus blood level, while alterations of the 321 allele resulted in significantly greater trough drug levels. It was also recently demonstrated that cyclosporine and tacrolimus are inhibitors of the organic anion transporters, so that one cannot exclude the possibility that these drugs may be substrates of \textit{OATP1B1} and \textit{OATP1B3} as well.

**Angiotensinogen C3889T (rs4762) gene polymorphism**

It is well known that tacrolimus has a negative effect on pancreatic beta islet cells and can cause glucose intolerance and diabetes mellitus\textsuperscript{[24]}.

However, new studies have suggested that post-transplant diabetes mellitus can also be related to other factors and, consequently, not only to tacrolimus administration\textsuperscript{[124,125]}. Angiotensinogen (AGT) is the initial component of the renin-angiotensin system (RAS) and a precursor of both angiotensin I and II. In a study on 302 subjects, the authors found that the AGT gene polymorphism (rs4762) is associated with post-transplant diabetes mellitus, due to insulin resistance, in Korean renal transplant patients\textsuperscript{[126]}. Molecular and genetic studies demonstrate a relationship between variants of the AGT gene, AGT gene expression and plasma AGT levels\textsuperscript{[127,128]}. However, the association between this gene and glucose metabolism remain controversial.

**DISCUSSION**

As clinical trials continue to evaluate the influence of genetics on drug dosing and response, the challenge now becomes to assess the potential clinical implications of this research for medical practice. Sufficient data has been accumulated to be certain that the liver donors and renal re-
Recipient CYP3A5 genotype has important influences on tacrolimus dosing and on its blood levels through metabolism. However, it remains the question whether genotyping should become a standard practice in transplantation.

This question is difficult to answer because of the multi-factorial approach needed to assess the pharmacokinetic profile of a drug. Wide variability of tacrolimus dosing requirements to reach target blood levels has been observed among patients carrying the same genotype. This underlies the fact that genetic polymorphisms are only one of the possible factors that can influence tacrolimus pharmacokinetics. Patient age, race, metabolic level, concomitant medications and a variety of other environmental factors appear to play an even more significant role than genotype in altering drug pharmacokinetics. Specifically in liver transplant patients, time after transplantation also plays a critical role in altering drug metabolism and distribution.

To further complicate the issue, studies have yet to demonstrate a clear association between tacrolimus blood trough levels, genotype and transplant outcomes. Organ rejection and drug toxicities have been seen to develop in patients without any notable difference in tacrolimus blood concentration, making difficult to predict the optimal trough drug targets in relationship to the characteristics of the individual patient. Toxicities associated with tacrolimus are also often difficult to study because of their insidious onset. Hypertension, hyperlipidemia and NODAT develop slowly over a period of many years, making the length of a trial an issue when one wants to monitor these chronic medication effects. The mechanisms of such adverse effects are, again, not fully understood and require further research to determine the need to genotype patients, not only as a way of lowering the incidence of organ rejection, but also of preventing drug toxicity after transplantation.

Studies in transplantation are also often difficult to conduct because of the limited patient population. Many studies involve fewer than 100 patients, which may help explain some of the variable results. A number of these studies also differ in their pharmacokinetic methods, dosing strategies, times when blood drug concentrations are assessed and patient’s characteristics. Differences between donor and recipient organ genotypes may also have confounded the results of some studies, as the genetics of both the recipient and of the donor were not always taken into account.

Genotyping is an attractive option for starting the dosing of tacrolimus; also, unlike phenotypic tests, the results of which may vary with environmental factors, the genotype is a stable characteristic that needs to be determined only once for any given gene. However, to ultimately prove the usefulness of genotyping, prospective clinical studies must show that genotype determination before transplantation allows the better use of a given drug and improves the safety and clinical efficacy of that medication. Currently Amplichip, a genetic test manufactured by Roche Pharmaceuticals, can determine a patient’s CYP2D6 and CYP2C19 polymorphisms for between United States $350 and $400, not including the mark up and other costs associated with the test. As a result, to offset the cost of genetic testing, genotypic analyses must demonstrate the ability to significantly improve transplant patient outcomes, in particular, graft life and patient survival, and show a cost saving for patients and for the health care system as a whole.

CONCLUSION
At present, research has been able to reliably show that the CYP3A5, but not the CYP3A4 or ABCB1, genotype modifies the pharmacokinetics of tacrolimus. However, it has not been possible to incontrovertibly show that the corresponding changes in the pharmacokinetic profile are linked with different patient outcomes regarding tacrolimus efficacy and toxicity. Additionally, given the high cost of genotypic tests and the wide availability and utility of therapeutic drug monitoring, genotyping all transplant patients is not convenient for many individuals or Institutions. This may change in the near future as further studies on pharmacogenetics will produce new data and the improvements in the genotyping analyses will drive down the costs associated with this type of tests. For these reasons, pharmacogenetics and individualized medicine remain a fascinating area for further study and may ultimately become the face of future medical practice and drug dosing.

REFERENCES
1. Murray JE, Tilney NL, Wilson RE. Renal transplantation: a twenty-five year experience. Ann Surg 1976; 184:565-573 [PMID: 791162]
2. Penninga L, Wettergren A, Chan AW, Steinbrüchel DA, Gluud C. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 2012; 3:CD008852 [PMID: 22419339 DOI: 10.1002/14651858.CD008852]
3. Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc 2011; 43: 2439-2440 [PMID: 21839286 DOI: 10.1016/j.transproceed.2011.06.025]
4. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1999; 25: 404-430 [PMID: 8787947]
5. Undre NA, Stevenson P, Schäfer A. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999; 31: 215-245 [PMID: 10576037]
6. Busch K, Gander P. Pharmacokinetic principles of immunosuppressive drugs. Ann Transplant 2008; 13: 5-10 [PMID: 18806727]
kinetics of tacrolimus (FK506) in kidney transplant recipients.-importance of trough level as a practical indicator. Int J Urol 1995; 2: 151-155 [PMID: 8536129]

42 Jusko WJ. Analysis of tacrolimus (FK 506) in relation to thera-peutic drug monitoring. Ther Drug Monit 1995; 17: 596-601 [PMID: 8588227]

43 Herrera MJ, Sánchez-Plumed J, Galiana M, Bea S, Marqués MR, Aliño SF. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant Proc 2010; 42: 3134-3136 [PMID: 20907628 DOI: 10.1016/j.transproceed.2010.05.122]

44 Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (online). Consulted 2013, June 03. Available from: URL: http://www.cypalleles.ki.se/

45 Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229 [PMID: 9719084]

46 Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67: 48-56 [PMID: 10668855]

47 Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hagase-wa Y, Kobayashi S, Katsumata Y, Shimokota K, Saito H. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1999; 91: 1587-1590 [PMID: 10491442]

48 Westling A, Lothberg L, Tjindberg N, Andersson TB, Ingel-man-Sunderland M. Interindividual differences in hepatic ex-pression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-205 [PMID: 10334940]

49 Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132 [PMID: 11875366]

50 Spurde AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chevenix-Trench G, Liddle C. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002; 12: 355-366 [PMID: 12142725]

51 Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochim Biophys Acta Res Commun 2005; 338: 299-305 [PMID: 16171783]

52 Amirini B, Walker AH, Weber BL, Rebbeck TR. RE-SPONSE: re. modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 1999; 91: 1588-1590 [PMID: 10491443]

53 Amirini B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Reb-beck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2005; 42: 299-305 [PMID: 14678375]

54 Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic vari-ant in the 5' promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66: 288-294 [PMID: 10511065]

55 García-Martín E, Martínez C, Pizarro RM, García-Gamito FJ, Martínez A, Sanchez-Plumed J, Ballesteros A, Vizcaino S, Gasiba C, Carrillo JA. Differences in CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Clin Pharmacol Ther 2000; 68: 82-91 [PMID: 10941539]

56 Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contri-bution to variable human CYP3A4-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294 [PMID: 12466645]

57 Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijsen RH, Vorwosta J, Figg WD, Sparnsho A. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A isoform in Heart transplant recipients in cancer patients. Clin Cancer Res 2005; 11: 7398-7404 [PMID: 16243813]

58 Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, May-ayo E, Conde B, Arenaz I, Martinez-Jarreta B. CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Other Caucasian populations. Ther Drug Monit 2007; 29: 412-416 [PMID: 1766794]

59 Gervasini G, Vizzacino S, Gasiba C, Carrillo JA. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Cau-sasion populations. Ther Drug Monit 2005; 27: 819-821 [PMID: 16308681]

60 Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrightson SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Verkatermanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorph CYP3A5 expression. Nat Genet 2001; 27: 383-391 [PMID: 11279519]

61 Hustert E, Haberl M, Burk O, Wollbold R, He YQ, Klein K, Nuesler AC, Neuhaus P, Klettig J, Eiselt R, Koch I, Zibat A, Brockmuller J, Halpert JR, Zanger UM, Wopfani L. The genetic determinants of the CYP3A5 polymorphism. Pharmacoge-netics 2001; 11: 773-779 [PMID: 11740341]

62 Goto M, Masuda S, Kuchi T, Ogura Y, Oke F, Okuda M, Tanaka K, Inui K. CYP3A5*1-carrying graft liver reduces the concentra-tion/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471-478 [PMID: 15226679]

63 Joy MS, Hogan SL, Thompson BD, Finn WF, Niccollet V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007; 22: 1963-1968 [PMID: 17395652]

64 Zheng S, Tarsiul MF, Hebert MF, Davis CL, Shibata Y, Calamia JC, Lin YS, Shen DD, Thummel KE. Measurement and compara-tmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 2012; 92: 737-745 [PMID: 23077528 DOI: 10.1038/ clinpharm.2012.175]

65 Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplan-tant recipients. Gene 2013; 512: 226-231 [PMID: 23107770 DOI: 10.1016/j. gene.2012.10.048]

66 Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor P, Lindemans J, Weinmar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibi-tors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254 [PMID: 12966368]

67 Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, vanRenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711-725 [PMID: 17498800]

68 Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weinmar W, Mathom RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556 [PMID: 15992526]

69 Riordan JR, Deuchars K, Kattner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant
mammalian cell lines. Nature 1985; 316: 817-819 [PMID: 2863799]

Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Semin Cell Biol 1997; 8: 135-142 [PMID: 9491443]

Ganapathy V, Prasad PD, Ganapathy M, Leibach FH. Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 2000; 294: 413-420 [PMID: 10900213]

Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168 [PMID: 11327196]

Fojo AT, Ueda K, Slamov D, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269 [PMID: 2432605]

Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, Lee CG. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437-450 [PMID: 12172212]

Anglicheau D, Thervet E, Etienne I, Hurault De Lifvy B, Le Meur Y, Touchard G, Bächer M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433 [PMID: 15116055]

Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrini TE, DeYoung J, Taylor T, Carlson EJ, Hershkovitz I, Giacomini KM, Clark AG. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481-494 [PMID: 12893896]

Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. Pharmacogenetics 2008; 18: 248-255 [PMID: 17709595]

Yamauchi A, Ieiri I, Katoaka Y, Tanabe M, Nishizaki T, Oishi R, Yanagimachi M, Naruto T, Tanoshima R, Kato H, Yokosuka T, Ueda K, Uemoto S, Ieiri K. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413-423 [PMID: 18408564 DOI: 10.1097/FGA.0b013e328289ac01]

Provenza A, Notarbartolo M, Labbozzetta M, Poma P, Biondi F, Sanguedolco R, Vizzini G, Palazzo U, Polidori P, Triolo F, Gridelli B, D’Alessandro N. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. Ann Transplant 2009; 14: 23-31 [PMID: 19288993]

Provenza A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D’Alessandro N. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 2011; 27: 1093-1102 [PMID: 21922127 DOI: 10.3892/ijmm.2011.774]

Provenza A, Notarbartolo M, Labbozzetta M, Poma P, D’Antora A, Polidori P, Vizzini G, D’Alessandro N. Unusual high dose of tacrolimus in liver transplant patient, a case report. Int J Clin Pharmacol 2012; 34: 269-271 [PMID: 22422348 DOI: 10.1007/s11096-012-9296-2]

Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F, Alamo-Martinez JM, Pareja-Ciuro F, Nuñez-Roldán A, Gómez-Bravo MA, Bernardos-Rodriguez A. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc 2008; 40: 2949-2951 [PMID: 19010156 DOI: 10.1016/j.transproceed.2008.09.016]

Chakera HA, Chang YH, Bodner JK, Behmnen S, Heiland RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Fassettia LA. Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. Transplant Proc 2013; 45: 137-141 [PMID: 2375287 DOI: 10.1016/j.transproceed.2012.10.023]

Gladowcki J, Lionetta A, Bocchi D, Labellette M, Allorge D, Provét F, Hassanz M, Noël C, Broly F, Cauffeize C, CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant 2011; 26: 3046-3050 [PMID: 21677300 DOI: 10.1093/ndt/gfr253]

López-Montenegro Soria MA, Kanter Berga J, Beltrán Catalán S, Milara Payá J, Pallardó Mateu LM, Jiménez Torres NV. Genetic polymorphisms and individualized tacrolimus dosing.
Provenzano A et al. Pharmacogenetic considerations for optimizing tacrolimus dosing

Transplant Proc 2010; 42: 3031-3033 [PMID: 20970601]

Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among renal transplant recipients in Korea. Transplantation 2009; 87: 1225-1231 [PMID: 19384171 DOI: 10.1097/TP.0b013e318191f117]

Elen S, Capron A, Kerkhove VV, Lerut J, Mourad M, Lison D, Wallemacq P, Haufrond V. 1196G→A; and 2677G→G; T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomics 2005; 17: 873-883 [PMID: 17886526]

Macphee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, Goldberg L, Holt DW. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asian. Transplantation 2005; 79: 499-502 [PMID: 15729180]

Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Fogamp P, Moulin B, Le Mear Y, Heng AE, Subra JF, Beaune P, Legendre F. Optimization of initial tacrolimus dose using pharmacogenetic testing, Clin Pharmacol Ther 2010; 87: 721-726 [PMID: 20395454 DOI: 10.1038/cpt.2010.17]

Speriaings N, Holt DW, Macphee IA. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit 2013; 35: 328-331 [PMID: 23666381 DOI: 10.1097/FTD.0b013e3182964461]

Chen SY, Li JL, Meng FH, Wang XD, Liu T, Li JI, Liu LS, Fu Q, Huang M, Wang CX. Individualization of tacrolimus-dosage based on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study, Clin Transplant 2013; 27: E272-E281 [PMID: 23432535 DOI: 10.1111/clt.12101]

Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32: 394-404 [PMID: 20526235 DOI: 10.1097/FTD.0b013e3181e69818]

Tsay JS, Lamba V, Nachman K, Liao SS, Ma S, Chien Y, Hsu F, Lam SK, Kung CM, Chiu ML, Chao BS. CYP3A5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 2013; 51: 466-474 [PMID: 23557867 DOI: 10.5414/CP201183]

Elen S, van Gelder T, Hesselink DA, Haufrond V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy, Pharmacogenomics 2013; 14: 47-62 [PMID: 23252948 DOI: 10.2217/pgs.12.187]

Elens L, Bouzamr R, Hesselink DA, Haufrond V, van der Heijden IP, van Gelder T, van Schaik RH. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583 [PMID: 21903774 DOI: 10.1373/clinchem.2011.156613]

Wang D, Guo Y, Wrightson SA, Cooke GE, Sadee W. Intrinsic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmaceuticals 2011; 11: 274-286 [PMID: 22086561 DOI: 10.3390/tp.2011.028]

Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C→G t; polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 2013; 38: 439-354 [PMID: 23665933]

Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Mezina-Pestana JO, Suarez-Kurtz G. CYP3A5 genotype, but not CYP3A4*1B, CYP3A4*22, or hemocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin Pharmacol Ther 2013; 94: 201-202 [PMID: 23588314 DOI: 10.1038/cpt.2013.68]

Smith HE, Jones JP, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, Perkins JD, Blough DK, Hebert MF, Thumbel KE, Totah CL, Perkins JD, Blough DK, Hebert MF, Thumbel KE, Totah RA. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmazie 2012; 67: 943-953 [PMID: 18769365 DOI: 10.1691/ph.2012.16]

Gervasini G, García M, Macías RM, Benítez J, Caravaca F, Cubero J. CYP2C9 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013; 53: 427-434 [PMID: 23426460 DOI: 10.1002/jcph.15]

Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, Griffith BP, Fricker FJ. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. J Heart Lung Transplant 1997; 16: 275-282 [PMID: 9087607]

Ippoliti GB, Viganò M. [Calcineurin inhibitors and mechanisms that are responsible for the appearance of post-transplant diabetes mellitus]. G Ital Nefrol 2003; 20 Suppl: S11-S14 [PMID: 14532907]

Lee SR, Moon JY, Lee SH, Ihm CG, Lee TW, Kim SK, Chung JH, Kang SW, Kim TH, Park SJ, Kim YH, Jeong KH. Angiotensino-
Provenzani A et al. Pharmacogenetic considerations for optimizing tacrolimus dosing

gen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects. Kidney Blood Press Res 2013; 37: 95-102 [PMID: 23594830 DOI: 10.1159/000343404]

127 Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786-1797 [PMID: 9120024]

128 Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92: 2735-2739 [PMID: 7708716]

P- Reviewers: Markic D, Taheri S
S- Editor: Wen LL  L- Editor: A  E- Editor: Liu XM